Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSBR NASDAQ:INMB NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$6.19-4.8%$5.97$5.50▼$9.63$85.97M0.418,536 shs4,425 shsINMBINmune Bio$1.30+4.4%$1.37$1.09▼$11.64$34.42M1.03402,103 shs39,889 shsXFORX4 Pharmaceuticals$4.03+0.6%$4.09$1.35▼$4.83$379.64M0.34435,741 shs58,649 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology0.00%+15.49%+5.24%+4.74%-15.80%INMBINmune Bio0.00%-1.59%-20.00%-8.15%-83.90%XFORX4 Pharmaceuticals0.00%+4.44%+1.52%+12.36%+41.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$6.19-4.8%$5.97$5.50▼$9.63$85.97M0.418,536 shs4,425 shsINMBINmune Bio$1.30+4.4%$1.37$1.09▼$11.64$34.42M1.03402,103 shs39,889 shsXFORX4 Pharmaceuticals$4.03+0.6%$4.09$1.35▼$4.83$379.64M0.34435,741 shs58,649 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology0.00%+15.49%+5.24%+4.74%-15.80%INMBINmune Bio0.00%-1.59%-20.00%-8.15%-83.90%XFORX4 Pharmaceuticals0.00%+4.44%+1.52%+12.36%+41.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSBRChampions Oncology 1.00SellN/AN/AINMBINmune Bio 2.17Hold$8.00517.76% UpsideXFORX4 Pharmaceuticals 2.50Moderate Buy$9.38132.92% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, XFOR, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026INMBINmune Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/4/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026XFORX4 Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.005/22/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/27/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSBRChampions Oncology$57.95M1.48$0.44 per share14.17$0.27 per share22.93INMBINmune Bio$50K688.42N/AN/A$0.88 per share1.47XFORX4 Pharmaceuticals$35.11M10.81N/AN/A$2.13 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSBRChampions Oncology$4.70M-$0.16N/AN/AN/A-3.94%-57.31%-7.51%7/16/2026 (Estimated)INMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.54N/AN/AN/A-1,106.30%-94.90%-48.09%8/6/2026 (Estimated)Latest CSBR, XFOR, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/A5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 million3/30/2026Q4 2025INMBINmune Bio-$0.27-$0.18+$0.09-$0.18($0.01) millionN/A3/17/2026Q4 2025XFORX4 Pharmaceuticals-$0.36-$0.22+$0.14$1.00$1.68 million$2.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSBRChampions OncologyN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSBRChampions OncologyN/A0.980.98INMBINmune BioN/A4.244.24XFORX4 Pharmaceuticals0.4510.189.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSBRChampions Oncology41.30%INMBINmune Bio12.72%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipCSBRChampions Oncology46.98%INMBINmune Bio21.40%XFORX4 Pharmaceuticals1.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSBRChampions Oncology14313.89 million7.44 millionOptionableINMBINmune Bio1026.58 million20.90 millionOptionableXFORX4 Pharmaceuticals8094.32 million93.25 millionNo DataCSBR, XFOR, and INMB HeadlinesRecent News About These CompaniesX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Rating of "Moderate Buy" by BrokeragesJune 5, 2026 | americanbankingnews.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comHow The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU ProgressMay 21, 2026 | finance.yahoo.comBears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' NowMay 20, 2026 | zacks.comX4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should KnowMay 18, 2026 | zacks.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 15, 2026 | finance.yahoo.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comGuggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 11, 2026 | theglobeandmail.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6, 2026 | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) price target increased by 25.00% to 11.90March 27, 2026 | msn.comX4 Jumps on Q4 FiguresMarch 17, 2026 | baystreet.caX4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesMarch 17, 2026 | zacks.comX4 Pharmaceuticals Reports Positive EMA Opinion on Mavorixafor and Updates on 4WARD Phase 3 Trial Enrollment ProgressMarch 17, 2026 | quiverquant.comQX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSBR, XFOR, and INMB Company DescriptionsChampions Oncology NASDAQ:CSBR$6.19 -0.31 (-4.75%) As of 10:37 AM Eastern This is a fair market value price provided by Massive. Learn more.Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.INmune Bio NASDAQ:INMB$1.30 +0.06 (+4.44%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.X4 Pharmaceuticals NASDAQ:XFOR$4.03 +0.03 (+0.63%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
